Ketamine as a novel antidepressant: From synapse to behavior

Clinical Pharmacology and Therapeutics

Volumn 91, Issue 2, 2012, Pages 303-309

  Murrough, J W ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPA RECEPTOR; KETAMINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2A;

ARTICLE; BEHAVIOR; HUMAN; LOW DRUG DOSE; MAJOR DEPRESSION; NONHUMAN; PRIORITY JOURNAL; SUICIDAL BEHAVIOR; SYNAPSE; TREATMENT RESISTANT DEPRESSION;

ANIMALS; ANTIDEPRESSIVE AGENTS; BRAIN; CLINICAL TRIALS AS TOPIC; DEPRESSIVE DISORDER, TREATMENT-RESISTANT; DISEASE MODELS, ANIMAL; HUMANS; KETAMINE; NEURAL PATHWAYS; SYNAPTIC TRANSMISSION;

EID: 84855940822     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2011.244     Document Type: Article

References (41)

1. Kessler, R.C. et al.; National Comorbidity Survey Replication. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA 289, 3095-3105 (2003). (Pubitemid 37432885)
2. American Psychiatric Association. Task Force on DSM-IV. Diagnostic and Statistical Manual of Mental Disorders. 4th edn., text revision (American Psychiatric Association, Washington, DC, 2000).
3. Rush, A.J. et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am. J. Psychiatry 163, 1905-1917 (2006). (Pubitemid 44807782)
4. Rush, A.J. et al. Combining medications to enhance depression outcomes (CO-MED): acute and long-term outcomes of a single-blind randomized study. Am. J. Psychiatry 168, 689-701 (2011).
5. Krishnan, V. & Nestler, E.J. The molecular neurobiology of depression. Nature 455, 894-902 (2008).
6. Manji, H.K. et al. Enhancing neuronal plasticity and cellular resilience to develop novel, improved therapeutics for difficult-to-treat depression. Biol. Psychiatry 53, 707-742 (2003). (Pubitemid 39658487)
7. Berman, R.M. et al. Antidepressant effects of ketamine in depressed patients. Biol. Psychiatry 47, 351-354 (2000). (Pubitemid 30109248)
8. Zarate, C.A. Jr et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch. Gen. Psychiatry 63, 856-864 (2006). (Pubitemid 44188478)
9. Mathew, S.J., Murrough, J.W., aan het Rot, M., Collins, K.A., Reich, D.L. & Charney, D.S. Riluzole for relapse prevention following intravenous ketamine in treatment-resistant depression: a pilot randomized, placebocontrolled continuation trial. Int. J. Neuropsychopharmacol. 13, 71-82 (2010).
10. aan het Rot, M. et al. Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression. Biol. Psychiatry 67, 139-145 (2010).
11. Murrough, J.W., Perez, A.M., Mathew, S.J. & Charney, D.S. A case of sustained remission following an acute course of ketamine in treatment-resistant depression. J. Clin. Psychiatry 72, 414-415 (2011).
12. Price, R.B., Nock, M.K., Charney, D.S. & Mathew, S.J. Effects of intravenous ketamine on explicit and implicit measures of suicidality in treatmentresistant depression. Biol. Psychiatry 66, 522-526 (2009).
13. DiazGranados, N. et al. Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatmentresistant major depressive disorder. J. Clin. Psychiatry 71, 1605-1611 (2010).
14. Larkin, G.L. & Beautrais, A.L. A preliminary naturalistic study of low-dose ketamine for depression and suicide ideation in the emergency department. Int. J. Neuropsychopharmacol. 14, 1127-1131 (2011).
15. Trullas, R. & Skolnick, P. Functional antagonists at the NMDA receptor complex exhibit antidepressant actions. Eur. J. Pharmacol. 185, 1-10 (1990). (Pubitemid 20254891)
16. Skolnick, P., Layer, R.T., Popik, P., Nowak, G., Paul, I.A. & Trullas, R. Adaptation of N-methyl-D-aspartate (NMDA) receptors following antidepressant treatment: implications for the pharmacotherapy of depression. Pharmacopsychiatry 29, 23-26 (1996). (Pubitemid 26072654)
17. Li, N. et al. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science 329, 959-964 (2010).
18. Autry, A.E. et al. NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses. Nature 475, 91-95 (2011).
19. Li, N. et al. Glutamate N-methyl-D-aspartate receptor antagonists rapidly reverse behavioral and synaptic deficits caused by chronic stress exposure. Biol. Psychiatry 69, 754-761 (2011).
20. Machado-Vieira, R. et al. Brain-derived neurotrophic factor and initial antidepressant response to an N-methyl-D-aspartate antagonist. J. Clin. Psychiatry 70, 1662-1666 (2009).
21. Garcia, L.S. et al. Ketamine treatment reverses behavioral and physiological alterations induced by chronic mild stress in rats. Prog. Neuropsychopharmacol. Biol. Psychiatry 33, 450-455 (2009).
22. Duman, R.S. & Monteggia, L.M. A neurotrophic model for stress-related mood disorders. Biol. Psychiatry 59, 1116-1127 (2006).
23. Maeng, S. et al. Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors. Biol. Psychiatry 63, 349-352 (2008). (Pubitemid 351146651)
24. Price, J.L. & Drevets, W.C. Neurocircuitry of mood disorders. Neuropsycho pharmacology 35, 192-216 (2010).
25. Murrough, J.W., Iacoviello, B., Neumeister, A., Charney, D.S. & Iosifescu, D.V. Cognitive dysfunction in depression: Neurocircuitry and new therapeutic strategies. Neurobiol. Learn. Mem. (2011); e-pub ahead of print 16 June 2011.
26. Moghaddam, B., Adams, B., Verma, A. & Daly, D. Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J. Neurosci. 17, 2921-2927 (1997). (Pubitemid 27155025)
27. Homayoun, H. & Moghaddam, B. NMDA receptor hypofunction produces opposite effects on prefrontal cortex interneurons and pyramidal neurons. J. Neurosci. 27, 11496-11500 (2007). (Pubitemid 350006886)
28. Vollenweider, F.X. et al. Metabolic hyperfrontality and psychopathology in the ketamine model of psychosis using positron emission tomography (PET) and [18F]fluorodeoxyglucose (FDG). Eur. Neuropsychopharmacol. 7, 9-24 (1997). (Pubitemid 27139716)
29. Långsjö, J.W. et al. Effects of subanesthetic doses of ketamine on regional cerebral blood flow, oxygen consumption, and blood volume in humans. Anesthesiology 99, 614-623 (2003). (Pubitemid 37051976)
30. Långsjö, J.W. et al. Effects of subanesthetic ketamine on regional cerebral glucose metabolism in humans. Anesthesiology 100, 1065-1071 (2004). (Pubitemid 38541959)
31. Holcomb, H.H., Lahti, A.C., Medoff, D.R., Cullen, T. & Tamminga, C.A. Effects of noncompetitive NMDA receptor blockade on anterior cingulate cerebral blood flow in volunteers with schizophrenia. Neuropsychopharmacology 30, 2275-2282 (2005). (Pubitemid 41643980)
32. Deakin, J.F., Lees, J., McKie, S., Hallak, J.E., Williams, S.R. & Dursun, S.M. Glutamate and the neural basis of the subjective effects of ketamine: a pharmaco-magnetic resonance imaging study. Arch. Gen. Psychiatry 65, 154-164 (2008). (Pubitemid 351214314)
33. Rowland, L.M. et al. Effects of ketamine on anterior cingulate glutamate metabolism in healthy humans: a 4-T proton MRS study. Am. J. Psychiatry 162, 394-396 (2005). (Pubitemid 40216226)
34. Taylor, M.J., Tiangga, E.R., Ní Mhuircheartaigh, R. & Cowen, P. Lack of effect of ketamine on cortical glutamate and glutamine in healthy volunteers: a proton magnetic resonance spectroscopy study. J. Psychopharmacol. (2011); e-pub ahead of print 26 May 2011.
35. Covington, H.E. 3rd et al. Antidepressant effect of optogenetic stimulation of the medial prefrontal cortex. J. Neurosci. 30, 16082-16090 (2010).
36. Salvadore, G. et al. Increased anterior cingulate cortical activity in response to fearful faces: a neurophysiological biomarker that predicts rapid antidepressant response to ketamine. Biol. Psychiatry 65, 289-295 (2009).
37. Salvadore, G. et al. Anterior cingulate desynchronization and functional connectivity with the amygdala during a working memory task predict rapid antidepressant response to ketamine. Neuropsychopharmacology 35, 1415-1422 (2010).
38. Phelps, L.E., Brutsche, N., Moral, J.R., Luckenbaugh, D.A., Manji, H.K. & Zarate, C.A. Jr. Family history of alcohol dependence and initial antidepressant response to an N-methyl-D-aspartate antagonist. Biol. Psychiatry 65, 181-184 (2009).
39. Garcia, L.S. et al. Acute administration of ketamine induces antidepressantlike effects in the forced swimming test and increases BDNF levels in the rat hippocampus. Prog. Neuropsychopharmacol. Biol. Psychiatry 32, 140-144 (2008).
40. Koike, H., Iijima, M. & Chaki, S. Involvement of AMPA receptor in both the rapid and sustained antidepressant-like effects of ketamine in animal models of depression. Behav. Brain Res. 224, 107-111 (2011).
41. Diazgranados, N. et al. A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression. Arch Gen Psychiatry 67(8), 793-802 (2010).